Five-fraction SBRT showed encouraging early safety in frail stage III NSCLC
Sequential chemotherapy plus five-fraction SBRT produced 86.7% one-year local control with 7.7% acute grade 3 toxicity in STARLORD.
Tag
phase-2
Hemithoracic radiotherapy after surgery achieved durable control in pleural thymoma
After surgery and 14 Gy hemithoracic radiotherapy, five-year progression-free survival was 50.8% with only one grade 3 pneumonitis.
Five-fraction prostate and pelvic SABR showed durable control with low late toxicity
Five weekly SABR fractions to prostate and pelvic nodes produced 10.5% five-year biochemical failure with low persistent gastrointestinal and urinary toxicity.
Tetrandrine trial will test prevention of lung injury during esophageal chemoradiotherapy
A randomized phase II trial will test whether intravenous tetrandrine reduces grade 2 or higher lung injury from 25% to 10%.
Durvalumab with radiotherapy achieved 39% two-year PFS in cCRT-ineligible NSCLC
Concurrent and consolidative durvalumab with definitive radiotherapy produced 39% two-year progression-free survival in patients ineligible for concurrent chemoradiotherapy.